US Patent 8,858,996: Scope, Claims, Expiration, Orange Book Status, and Vimovo Patent Landscape

US Patent 8,858,996 protects a fixed-dose naproxen and esomeprazole tablet in which naproxen is delayed until exposure to a medium with a pH of at least 3.5, while esomeprazole is released independently of pH. The patent is directed primarily to the dosage-form architecture used for gastrointestinal protection during naproxen therapy, rather than to naproxen or esomeprazole as chemical substances.

The strongest infringement risk applies to multilayer tablets containing 200-600 mg of naproxen and 5-100 mg of esomeprazole, with naproxen in an acid-resistant core or layer and esomeprazole in a non-enteric, stomach-releasing layer.

What drug and formulation does US Patent 8,858,996 protect?

US 8,858,996 covers pharmaceutical tablets combining:

Naproxen as the anti-inflammatory and analgesic component.
Esomeprazole as the proton-pump inhibitor.
A release system that delays naproxen release until the dosage form reaches a pH of at least 3.5.
An esomeprazole layer that releases the active ingredient regardless of environmental pH.
A tablet configuration that can include a naproxen-containing core and one or more external layers.

The claimed formulation corresponds to the technology commercialized in Vimovo, a prescription fixed-dose combination of delayed-release naproxen and immediate-release esomeprazole magnesium. Vimovo was developed to provide anti-inflammatory treatment with suppression of naproxen-associated upper gastrointestinal adverse events.

The patent does not broadly cover every combination of naproxen and esomeprazole. The claims require a particular combination of active-ingredient amounts and release behavior.

What are the key claim limitations?

Claim element	Scope
Dosage form	Tablet in unit dosage form
Naproxen amount	200-600 mg per tablet in independent claim 1
Esomeprazole amount	5-100 mg per tablet in independent claim 1
Naproxen release	Inhibited unless medium pH is at least 3.5
Esomeprazole release	At least partly released regardless of medium pH
Tablet structure	May be multilayer, with a core and external layers
Naproxen location	Core layer in claims 2, 4 and 12
Esomeprazole location	At least one layer outside the core in claim 5
External layers	Must not contain naproxen under claim 6
Esomeprazole coating	Non-enteric film coating that releases esomeprazole in the stomach under claim 12
Therapeutic use	Treatment of pain or inflammation
Listed diseases	Osteoarthritis or rheumatoid arthritis

The pH threshold is a central limitation. A competing tablet that releases naproxen at a pH below 3.5 could avoid literal infringement of claims requiring the specified pH-dependent behavior, although the overall design could still raise doctrine-of-equivalents issues.

How do claims 1 through 11 of US 8,858,996 operate?

Claims 1 through 11 define a broad formulation and treatment-method group.

Claim 1: Broadest composition claim

Claim 1 requires a tablet containing:

Naproxen at 200-600 mg.
Esomeprazole at 5-100 mg.
pH-independent release of at least part of the esomeprazole.
Inhibited naproxen release unless pH reaches at least 3.5.

Claim 1 does not expressly require a multilayer structure or require the naproxen to be in a core. It can therefore reach a range of physical tablet designs if the release profile satisfies the claim.

The claim also does not specify a particular enteric polymer, coating thickness, dissolution test, manufacturing process, naproxen salt, esomeprazole salt, excipient, or compression method.

Claims 2 through 6: Structural narrowing

These claims narrow the architecture:

Claim 2 requires naproxen in a core with a coating that inhibits release below pH 3.5.
Claim 3 requires a multilayer tablet.
Claim 4 requires naproxen in the core layer.
Claim 5 requires esomeprazole in an external layer.
Claim 6 excludes naproxen from the layers outside the core.

Claims 3 through 6 are important for infringement analysis because they identify the physical arrangement that most closely resembles a bilayer or multilayer delayed-release tablet.

Claims 7 through 9: Formulation excipients

Claims 7 through 9 cover conventional formulation additions, including:

Carriers.
Lubricants.
Preservatives.
Disintegrants.
Stabilizers.
Wetting agents.
Emulsifiers.
Salts.
Buffers.
Coloring and flavoring agents.
pH-adjusting ingredients.

These claims add limited independent technical distinction because many commercial tablets use one or more of these excipients. Their value is that they preserve dependent-claim coverage over ordinary formulation practices.

Claims 10 and 11: Method-of-use claims

Claims 10 and 11 cover administering the claimed tablet to treat pain or inflammation, including pain or inflammation caused by:

Osteoarthritis.
Rheumatoid arthritis.

These method claims may be relevant to induced-infringement analysis if a generic label directs use for the claimed conditions. They are less likely to block approval independently if the product is already captured by composition claims.

What do claims 12 through 19 add?

Claims 12 through 19 define a more specific composition and method-of-treatment group.

Claim 12 requires:

A naproxen-containing core.
A coating that prevents naproxen release unless pH is at least 3.5.
A separate esomeprazole-containing layer.
A non-enteric film coating on the esomeprazole layer.
Esomeprazole release in the stomach.

Claims 13 through 15 add the active-ingredient amounts. Claim 15 requires both:

Naproxen at 200-600 mg.
Esomeprazole at 5-100 mg.

Claims 16 through 19 cover administration for pain or inflammation, including osteoarthritis and rheumatoid arthritis.

Claim 12 contains the phrase "wherein said layer is has a non-enteric film coating." The apparent grammatical error does not necessarily defeat the claim. Patent claims are generally interpreted in light of the specification and prosecution history, and the operative technical limitation is the requirement for a non-enteric film coating that releases esomeprazole in the stomach.

What is the likely claim construction of the pH and release limitations?

The pH language creates both the patent's technical focus and its principal enforcement boundary.

"Unless the pH ... is 3.5 or higher"

This language generally requires delayed or inhibited naproxen release in media below pH 3.5. A formulation may fall within the claim if naproxen release begins only after the dosage form reaches a pH of 3.5 or above.

Relevant evidence would include:

Dissolution testing at multiple pH levels.
Release curves for naproxen and esomeprazole.
Coating composition and coating weight.
Tablet cross-sections.
Product development documents.
ANDA formulation and batch records.

"Regardless of the pH of the medium"

This limitation requires esomeprazole release that is not dependent on an acidic-to-neutral pH transition in the same manner as naproxen. It is directed to immediate or substantially pH-independent esomeprazole release.

A formulation in which esomeprazole remains protected until intestinal pH could present a non-infringement position against claims requiring stomach release. Conversely, a formulation with an immediate-release esomeprazole layer and delayed-release naproxen core is close to the literal claim language.

"At least a portion"

The claims do not require complete release of all esomeprazole or naproxen. Partial release can satisfy the claim if the specified release behavior occurs for at least part of the active ingredient.

What patents protect Vimovo and the naproxen-esomeprazole combination?

The relevant US patent estate has included earlier combination patents and later patents directed to specific formulation configurations.

Patent	General subject matter	Relevance
US 6,926,907	Naproxen and esomeprazole pharmaceutical composition	Foundational combination and release technology
US 7,429,578	Related naproxen-esomeprazole formulation claims	Additional formulation protection
US 8,858,996	Tablet with pH-independent esomeprazole release and pH-dependent naproxen release	Specific multilayer/core-and-coating protection
FDA-listed Vimovo patents	Orange Book-listed patents associated with NDA 022511	Relevant to ANDA certification and litigation

US 8,858,996 is a formulation patent. It does not provide basic molecule-level exclusivity for naproxen or esomeprazole. Those active ingredients were already known and broadly available before the patent's filing.

The patent's commercial value lies in the combination of:

Fixed-dose coadministration.
Stomach release of esomeprazole.
Delayed naproxen release.
A multilayer tablet architecture.
Treatment of inflammatory pain while reducing acid-related exposure.

When does US Patent 8,858,996 expire?

The patent issued on October 14, 2014. Its term is based on the applicable US filing and priority history, subject to patent-term adjustment and any applicable patent-term extension.

Public patent records associate the patent with an expiration date in 2025, commonly reported as August 6, 2025 for the adjusted term. The relevant commercial exclusivity period is therefore formulation-specific and does not extend the underlying exclusivity of naproxen or esomeprazole as separate products.

Event	Date
Earliest priority history	November 3, 2004
US patent grant	October 14, 2014
Reported adjusted expiration	August 6, 2025
Product associated with the patent estate	Vimovo
Regulatory pathway for competitors	ANDA with Paragraph IV or Paragraph III certification

The exact enforceability of any Orange Book listing depends on the listing record, patent-term calculation, claim scope, and litigation outcome.

What is the Orange Book status of US 8,858,996?

The patent has been associated with the Vimovo NDA patent estate. Vimovo is an approved small-molecule fixed-dose combination regulated under an NDA, not a biologic license application.

The Orange Book relevance is significant because an ANDA applicant seeking approval of a generic naproxen and esomeprazole product must address listed patents through:

Paragraph I certification, if no patent information has been submitted.
Paragraph II certification, if the patent has expired.
Paragraph III certification, accepting approval after patent expiration.
Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed.

For a product with claims directed to the same multilayer release design, Paragraph IV exposure is substantial. A generic applicant could instead develop a materially different release system and seek a non-infringement position, depending on the Orange Book-listed claims and the product label.

FDA approval of a generic product is also affected by the four-year ANDA filing bar and any 30-month stay triggered by timely patent litigation under the Hatch-Waxman Act. FDA, U.S. Food and Drug Administration, Orange Book patent listings and the approved Vimovo labeling provide the principal regulatory sources for this analysis (FDA, 2024a, 2024b).

Which companies challenged or commercialized competing naproxen-esomeprazole products?

The competitive field has included the branded product owner and ANDA applicants seeking approval of generic equivalents.

Horizon and Vimovo

Vimovo was commercialized through the Pozen-AstraZeneca development and commercialization structure and later became associated with Horizon Pharma. Horizon acquired rights and commercial interests in the product as part of its gastrointestinal and specialty-pharmaceutical portfolio.

Generic applicants

Public Hatch-Waxman litigation and patent records have associated generic challenges with applicants including:

Dr. Reddy's Laboratories.
Actavis or Allergan-related entities.
Mylan-related entities.
Other ANDA applicants depending on the filing period and product configuration.

A Paragraph IV challenge does not itself establish invalidity or non-infringement. It initiates a statutory patent dispute and can delay approval while litigation proceeds.

What patent litigation affects Vimovo and US 8,858,996?

Vimovo-related litigation has centered on the validity, infringement, and enforceability of the listed combination patents. Typical disputes involve:

Whether the ANDA product uses the claimed pH-dependent naproxen release system.
Whether esomeprazole is released in the stomach.
Whether the proposed product has a core-and-layer or equivalent architecture.
Whether the claims are obvious over earlier naproxen, proton-pump inhibitor, and enteric-coating references.
Whether the patent claims adequately describe and enable the claimed release profile.
Whether the ANDA label induces use within osteoarthritis or rheumatoid arthritis treatment claims.

The litigation risk is strongest when the generic product copies the commercial release concept. It is lower when the applicant uses a different physical arrangement, a different coating strategy, or a distinct pH threshold.

Settlements in Hatch-Waxman cases can permit launch before patent expiry under agreed dates and conditions. The existence of a settlement does not eliminate the underlying patent claims, and settlement terms may include launch dates, licenses, supply restrictions, or acceleration provisions. The controlling dates must be taken from the specific district-court docket and settlement documents.

How strong is the patent estate for naproxen and esomeprazole?

The estate is strongest against a generic that reproduces the same release design. It is weaker against a product that separates the actives physically or changes the release mechanism.

Risk factor	Assessment
Basic active-ingredient protection	Low; both actives are long-established
Fixed-dose combination protection	Moderate to strong, depending on claim and prior art
Multilayer tablet coverage	Strong where product structure matches claims 3-6 and 12
pH-dependent naproxen release	Strong if the pH 3.5 threshold is met
Immediate stomach release of esomeprazole	Strong under claims 12-15
Method-of-use claims	Moderate; depends on label language
Manufacturing-process protection	Limited in the supplied claims
Biosimilar protection	Not applicable
Generic design-around potential	Moderate
Post-expiration enforcement	None for ordinary commercial use after valid expiration

The patent does not broadly claim every process for manufacturing the tablet. A competitor could potentially avoid the asserted claims through a different tablet architecture, separate dosage units, different release kinetics, or a formulation in which esomeprazole is not released in the stomach.

What generic launch scenarios exist?

Launch after patent expiration

This is the lowest litigation-risk scenario. A generic applicant accepts the listed patent and launches after the relevant patent term ends, subject to FDA approval and any other unexpired Orange Book patents or regulatory exclusivity.

Paragraph IV launch after litigation

An ANDA applicant may certify that the patent is invalid, unenforceable, or not infringed. If the patent owner sues within the statutory period, FDA approval may be stayed for up to 30 months, subject to court decisions and statutory exceptions.

Design-around launch

A competitor may use:

A different tablet arrangement.
A separate naproxen and esomeprazole dosage form.
A different esomeprazole release site.
A naproxen coating that responds at a different pH.
A formulation outside the claimed dosage ranges.

Design-around viability depends on the full Orange Book estate, not US 8,858,996 alone.

Authorized or licensed launch

A generic manufacturer may launch under a license or settlement with the patent holder. The commercial terms may be confidential, while the agreed launch date may appear in court filings or regulatory records.

Are biosimilars a risk to Vimovo?

No. Vimovo is a small-molecule combination tablet. Competitors pursue approval through the ANDA pathway for generic drugs, not through the biosimilar pathway under section 351(k) of the Public Health Service Act.

The relevant competitive threats are:

ANDA-approved generics.
Authorized generics.
Alternative naproxen plus proton-pump inhibitor regimens.
Separate prescriptions for naproxen and esomeprazole.
Other NSAID-gastroprotection combinations.

What is the geographic coverage of the patent?

US 8,858,996 provides protection in the United States only. Foreign counterparts may exist in Europe, Canada, Australia, and other jurisdictions, but each counterpart has an independent prosecution history, claim set, term, and litigation record.

A US formulation patent cannot block generic sales outside the United States. Conversely, foreign patents may expire on dates different from the US patent because of national filing dates, patent-term adjustments, supplementary protection certificates, opposition proceedings, or local regulatory extensions.

What manufacturing and intellectual-property barriers remain?

The main technical barrier is reproducing the required release profile at commercial scale. The formulation must maintain:

Naproxen protection in acidic conditions.
Naproxen release at or above pH 3.5.
Esomeprazole release independently of pH.
Physical separation or coating compatibility between the two active ingredients.
Stability of esomeprazole, which is acid-sensitive.
Tablet integrity during compression, coating, packaging, and storage.

These requirements create process-development costs even where a competitor avoids literal infringement. They do not, however, create a perpetual barrier. Once the relevant claims expire, manufacturing complexity becomes a technical and cost issue rather than a patent exclusivity issue.

Key Takeaways

US 8,858,996 is a formulation patent for naproxen and esomeprazole tablets.
The central limitation is delayed naproxen release below pH 3.5 combined with pH-independent esomeprazole release.
Claims 3-6 and 12-15 are particularly relevant to multilayer tablets with a naproxen core and an external esomeprazole layer.
Claims 10, 11 and 16-19 cover treatment of pain and inflammation, including osteoarthritis and rheumatoid arthritis.
The patent is associated with the Vimovo product and its Orange Book patent estate.
The reported adjusted expiration date is August 6, 2025.
Generic risk is highest for products that reproduce the same core-and-layer architecture and release profile.
Biosimilar competition is not relevant because Vimovo is a small-molecule tablet.
The patent protects a delivery system, not naproxen or esomeprazole as standalone active ingredients.
Generic launch may occur after expiration, through successful Paragraph IV litigation, under a settlement license, or through a technically credible design-around.

FAQs

Does US 8,858,996 cover generic naproxen tablets?

No. The claims require a combination of naproxen and esomeprazole with specified release behavior. Ordinary naproxen tablets are outside the claimed combination.

Does a separate naproxen tablet plus esomeprazole capsule infringe the patent?

Usually, the separate dosage units would not satisfy the claimed unit-dose tablet and multilayer composition limitations. The complete patent estate and any method-of-use theory would still require separate analysis.

What esomeprazole dose is within the independent claims?

Claim 1 covers 5-100 mg of esomeprazole per tablet. Claims 14 and 15 repeat that range for the more specific core-and-layer formulation.

Can a generic use an enteric-coated esomeprazole layer?

An enteric-coated esomeprazole layer may avoid the specific claim 12 requirement for a non-enteric film coating that releases esomeprazole in the stomach. It could remain exposed to other patents or claims, depending on the final product.

Does expiration of US 8,858,996 eliminate all Vimovo generic-entry barriers?

No. Generic entry also depends on other Orange Book-listed patents, regulatory exclusivity, FDA approval, litigation outcomes, settlement agreements, and the precise formulation submitted in the ANDA.

References

AstraZeneca. (2010). Vimovo prescribing information. U.S. Food and Drug Administration.
FDA, U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
FDA, U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs, Vimovo NDA 022511. U.S. Department of Health and Human Services.
U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,858,996: Pharmaceutical compositions comprising naproxen and esomeprazole. U.S. Department of Commerce.
U.S. Patent and Trademark Office. (2005). U.S. Patent Application Publication related to pharmaceutical compositions comprising naproxen and esomeprazole. U.S. Department of Commerce.
U.S. Patent and Trademark Office. (2009). U.S. Patent No. 7,429,578: Pharmaceutical compositions comprising naproxen and esomeprazole. U.S. Department of Commerce.
U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,926,907: Pharmaceutical compositions comprising an NSAID and a proton pump inhibitor. U.S. Department of Commerce.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1411900	⤷ Start Trial	C300481	Netherlands	⤷ Start Trial
European Patent Office	1411900	⤷ Start Trial	91858	Luxembourg	⤷ Start Trial
European Patent Office	1411900	⤷ Start Trial	1190013-1	Sweden	⤷ Start Trial
European Patent Office	1411900	⤷ Start Trial	CA 2012 00036	Denmark	⤷ Start Trial
European Patent Office	1411900	⤷ Start Trial	2011/016	Ireland	⤷ Start Trial
European Patent Office	1411900	⤷ Start Trial	SPC/GB11/015	United Kingdom	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,858,996